Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Phase 2 Completed 6 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: This phase II trial is studying how well umbilical cord blood transplantation works in treating patients with severe aplastic anemia, malignant thymoma, or myelodysplasia.

Timeline

Start: 1998-01
Primary completion: 2005-12
Completion: 2006-02

Publications

Background Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001 Jun 14;344(24):1815-22. doi: 10.1056/NEJM200106143442402.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Protein / enzyme biologic	—	—
Background	Busulfan	Small molecule	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Melphalan	Small molecule	—	—
Background	Methylprednisolone	Other / unclassified	—	—

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Summary

Timeline

Publications

Drugs

Indications